JP6666342B2 - 抗サイログロブリンｔ細胞レセプター - Google Patents

抗サイログロブリンｔ細胞レセプター Download PDF

Info

Publication number
JP6666342B2
JP6666342B2 JP2017525625A JP2017525625A JP6666342B2 JP 6666342 B2 JP6666342 B2 JP 6666342B2 JP 2017525625 A JP2017525625 A JP 2017525625A JP 2017525625 A JP2017525625 A JP 2017525625A JP 6666342 B2 JP6666342 B2 JP 6666342B2
Authority
JP
Japan
Prior art keywords
seq
tcr
amino acid
chain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017525625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536821A (ja
JP2017536821A5 (enExample
Inventor
賢一 花田
賢一 花田
ジェイ． ワン、チョン
ジェイ． ワン、チョン
シー． ヤン、ジェームズ
シー． ヤン、ジェームズ
ユ、ジヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2017536821A publication Critical patent/JP2017536821A/ja
Publication of JP2017536821A5 publication Critical patent/JP2017536821A5/ja
Application granted granted Critical
Publication of JP6666342B2 publication Critical patent/JP6666342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017525625A 2014-11-14 2015-11-12 抗サイログロブリンｔ細胞レセプター Active JP6666342B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079713P 2014-11-14 2014-11-14
US62/079,713 2014-11-14
PCT/US2015/060282 WO2016077525A2 (en) 2014-11-14 2015-11-12 Anti-human thyroglobulin t cell receptors

Publications (3)

Publication Number Publication Date
JP2017536821A JP2017536821A (ja) 2017-12-14
JP2017536821A5 JP2017536821A5 (enExample) 2018-12-20
JP6666342B2 true JP6666342B2 (ja) 2020-03-13

Family

ID=54704113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525625A Active JP6666342B2 (ja) 2014-11-14 2015-11-12 抗サイログロブリンｔ細胞レセプター

Country Status (6)

Country Link
US (3) US10450372B2 (enExample)
EP (2) EP3218404B1 (enExample)
JP (1) JP6666342B2 (enExample)
AU (1) AU2015346350C1 (enExample)
CA (1) CA2967778C (enExample)
WO (1) WO2016077525A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077525A2 (en) * 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human thyroglobulin t cell receptors
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
WO2023213904A1 (en) * 2022-05-04 2023-11-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts T cell receptor derived binding polypeptides
WO2024097652A2 (en) * 2022-10-31 2024-05-10 Legend Biotech Ireland Limited Anti-kras t cell receptors and engineered cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874845A (en) * 1984-06-13 1989-10-17 Massachusetts Institute Of Technology T lymphocyte receptor subunit
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2012166617A2 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
SI3514172T1 (sl) * 2014-04-01 2020-07-31 Biontech Cell & Gene Therapies Gmbh Claudin-6 specifični imunoreceptorji in T-celični epitopi
WO2016077525A2 (en) * 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human thyroglobulin t cell receptors

Also Published As

Publication number Publication date
EP3808770A1 (en) 2021-04-21
JP2017536821A (ja) 2017-12-14
CA2967778A1 (en) 2016-05-19
US20200102383A1 (en) 2020-04-02
CA2967778C (en) 2024-04-16
AU2015346350A1 (en) 2017-05-25
AU2015346350A2 (en) 2017-06-22
US20220389093A1 (en) 2022-12-08
AU2015346350B2 (en) 2021-06-24
WO2016077525A3 (en) 2016-12-29
US12275786B2 (en) 2025-04-15
US11440956B2 (en) 2022-09-13
WO2016077525A2 (en) 2016-05-19
US20180244768A1 (en) 2018-08-30
EP3218404B1 (en) 2021-01-06
EP3808770B1 (en) 2025-10-29
EP3218404A2 (en) 2017-09-20
AU2015346350C1 (en) 2022-01-06
US10450372B2 (en) 2019-10-22

Similar Documents

Publication Publication Date Title
JP7297807B2 (ja) 抗突然変異ｋｒａｓ ｔ細胞受容体
JP7461445B2 (ja) Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
US11466071B2 (en) HLA class I-restricted t cell receptors against mutated RAS
JP6628719B2 (ja) 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
US12275786B2 (en) Anti-thyroglobulin t cell receptors
US20200129555A1 (en) Hla-a3-restricted t cell receptors against mutated ras
US20250018039A1 (en) Hla-a3-restricted t cell receptors against ras with g12v mutation
US20240190940A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
HK40031837A (en) Anti-mutated kras t cell receptors
HK40031837B (en) Anti-mutated kras t cell receptors
HK1243642B (en) Anti-mutated kras t cell receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170725

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200220

R150 Certificate of patent or registration of utility model

Ref document number: 6666342

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250